Does OIVD Have the Cash and Talent to Regulate LDTs?

Perhaps most troubling is that it appears the FDA hasn't even begun to "speculate" on the kinds of funding or staffing upgrades OIVD will likely need to birth this kind of regulatory reform.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.